News

BMJ analysts have shown that since the FDA introduced the fast track approval procedure in 1992, many drugs (112) have not proven effective.

Due to widespread concerns about the protection of existing vaccines against new types of COVID-19, such as the delta variant, the minds of scientists and pharmacists are increasingly embraced by the idea of ​​using booster vaccination.

When it comes to high quality pharmaceuticals that comply with GMP certification, they may not contain minor ingredients.

According to Evaluate Pharma, the top 5 brightest innovations from large pharmaceutical companies include Tirzepatide and Donanemab (Eli Lilly - NPV 18, 7 and $ 17.9 billion), Deukravitinib (Bristol Myers Squibb, NPV $ 9.1 billion), Tirgolumab ( Roche, NPV $ 5.8 billion) and SAR442168 (tolebrutinib) (Sanofi, NPV $ 5.5 billion).